ARTICLE | Company News
Pharmexa, vectron deal
January 3, 2005 8:00 AM UTC
PHARMX acquired rights to Vectron's IP covering targeted liposomal delivery systems and single-chain diabodies, which are recombinant antibody-like proteins that PHARMX said can be used for passive im...